Comparison of Triamcinolone Acetonide Forms for Knee Osteoarthritis

This technical report presents a post hoc analysis comparing the effects of triamcinolone acetonide extended-release (TA-ER) and immediate-release (TA-IR) formulations on blood glucose levels in patients with knee osteoarthritis and type 2 diabetes. The study involved 33 participants who received intraarticular injections of either TA-ER or TA-IR. The analysis aimed to characterize the clinical relevance of the phase 2 study results, particularly focusing on hyperglycemia associated with corticosteroid injections. It details the study design, including inclusion criteria and outcome measures, such as changes in average daily glucose levels and time spent in target glycemic ranges. The findings indicate that TA-ER resulted in lower post-injection blood glucose levels and reduced time above the hyperglycemia threshold compared to TA-IR. The report concludes that TA-ER may offer better glucose control and fewer adverse events related to hyperglycemia, suggesting the need for further studies with larger sample sizes.